Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease

Brain

Volumn 122, Issue 9, 1999, Pages 1667-1678

  Harris, Gordon J ^a   Codori, Ann Marie ^b   Lewis, Robert F ^b   Schmidt, Eike ^b   Bedi, Asheesh ^b   Brandt, Jason ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Gene testing; Huntington's disease; MRI; Pre symptomatic; Single photon emission computed tomography (SPECT)

Indexed keywords

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; HUNTINGTON CHOREA; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; PUTAMEN; REGRESSION ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; BASAL GANGLIA; CEREBROVASCULAR CIRCULATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NUCLEAR FAMILY; PREDICTIVE VALUE OF TESTS; REGIONAL BLOOD FLOW; RISK; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRINUCLEOTIDE REPEATS; UNITED STATES;

EID: 0032860404     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/122.9.1667     Document Type: Article

References (53)

1. ACMG/ASHG (The American College of Medical Genetics/ American Society of Human Genetics) Huntington's Disease Genetic Testing Working Group. ACMG/ASHG statement: laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 1998; 62: 1243-7.
2. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. [Review]. Annu Rev Neurosci 1986; 9: 357-81.
3. Aylward EH, Schwartz J, Machlin S, Pearlson G. Bicaudate ratio as a measure of caudate volume in MR images. AJNR Am J Neuroradiol 1991; 12: 1217-22.
4. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994; 44: 823-8.
5. Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996; 53: 1293-6.
6. Bamford KA, Caine ED, Kido DK, Plassche WM, Shoulson I. Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology 1989; 39: 796-801.
7. Barr AN, Heinze WJ, Dobben GD, Valvassori GE, Sugar O. Bicaudate index in computerized tomography of Huntington disease and cerebral atrophy. Neurology 1978; 28: 1196-200.
8. Baxter L Jr, Mazziotta JC, Pahl JJ, Grafton ST, St. George-Hyslop P, Haines JL, et al. Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington's disease. Arch Gen Psychiatry 1992; 49: 148-54.
9. Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, et al. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. Ann Neurol 1988; 23: 541-6.
10. Bruyn GW. Huntington's chorea: historical, clinical and laboratory synopsis. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology, Vol. 6. Amsterdam: North-Holland; 1968. p. 298-378.
11. Carrasco LH, Mukherji CS. Atrophy of corpus striatum in normal male at risk of Huntington's chorea [letter]. Lancet 1986; 1: 1388-9.
12. Deckel AW, Cohen D, Duckrow R. Cerebral blood flow velocity decreases during cognitive stimulation in Huntington's disease. Neurology 1998; 51: 1576-83.
13. DeLong MR, Alexander GE, Miller WC, Crutcher MD. Anatomical and functional aspects of basal ganglia-thalamocortical circuits. In: Franks AJ, Ironside JW, Mindham RH, Smith RJ, Spokes EG, Winslow W, editors. Function and dysfunction in the basal ganglia. Manchester: Manchester University Press; 1990. p. 3-32.
14. Folstein SE. Huntington's disease: a disorder of families. Baltimore: Johns Hopkins University Press; 1989.
15. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
16. Folstein SE, Jensen B, Leigh JR, Folstein MF. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol 1983; 5: 605-9.
17. Garnett ES, Firnau G, Nahmias C, Carbotte R, Bartolucci G. Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease. J Neurol Sci 1984; 65: 231-7.
18. Grafton ST, Mazziotta JC, Pahl JJ, St. George-Hyslop P, Haines JL, Gusella J, et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol 1990; 28: 614-21.
19. Grafton ST, Mazziotta JC, Pahl JJ, St. George-Hyslop P, Haines JL, Gusella J, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992; 49: 1161-7.
20. Harris GJ, Pearlson GD. MRI-guided region of interest placement on emission computed tomograms. Psychiatry Res 1993; 50: 57-63.
21. Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol 1992; 31: 69-75.
22. Harris GJ, Aylward EH, Peyser CE, Pearlson GD, Brandt J, Roberts-Twillie JV, et al. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol 1996; 53: 316-24.
23. Hasselbalch SG, Oberg G, Sorensen SA, Andersen AR, Waldemar G, Schmidt JF, et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatry 1992; 55: 1018-23.
24. Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986; 36: 888-94.
25. Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WR. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology 1987; 37: 1441-7.
26. Hedreen JC, Folstein SE. Early loss of neostriatal strisome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995; 54: 105-20.
27. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes [see comments]. Cell 1993; 72: 971-83. Comment in: Cell 1993; 72: 817-8.
28. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes [see comments]. Cell 1993; 72: 971-83. Comment in: Cell 1993; 72: 817-8.
29. Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 1993; 34: 1274-81.
30. Jernigan TL, Salmon DP, Butters N, Hesselink JR. Cerebral structure on MRI, Part II: specific changes in Alzheimer's and Huntington's diseases. Biol Psychiatry 1991; 29: 68-81.
31. Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J. Cerebral metabolism and atrophy in Huntington's disease determined by 18-FDG and computed tomographic scan. Ann Neurol 1982; 12: 425-34.
32. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease. Psychiatry Res 1989; 29: 361-2.
33. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990; 113: 1405-23.
34. Kuwert T, Lange HW, Boecker H, Titz H, Herzog H, Aulich A, et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease [see comments]. J Neurol 1993a; 241: 31-6, Comment in: J Neurol 1995; 242: 112-4.
35. Kuwert T, Lange HW, Boecker H, Titz H, Herzog H, Aulich A, et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease [see comments]. J Neurol 1993a; 241: 31-6, Comment in: J Neurol 1995; 242: 112-4.
36. Kuwert T, Noth J, Scholz D, Schwarz M, Lange HW, Topper R, et al. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease. Mov Disord 1993b; 8: 98-106.
37. Lancaster JL, Glass TG, Lankipalli BR, Downs H, Mayberg H, Fox PT. A modality-independent approach to spatial normalization of tomographic images of the human brain. Hum Brain Mapp 1995; 3: 209-23.
38. Martin WR, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington's disease. Neurology 1992; 42: 223-9.
39. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Hoffman JM, et al. Studies in persons at risk for Huntington's disease. N Engl J Med 1987a; 317: 383-4.
40. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987b; 316: 357-62.
41. Oepen G, Ostertag C. Diagnostic value of CT in patients with Huntington's chorea and their offspring. J Neurol 1981; 225: 189-96.
42. Pantano P, Lenzi GL, Berardelli A, Passafiume D, Pozzilli C, Di Piero V. Regional CBF pattern in patients with Huntington's disease. J Cerebral Blood Flow Metab 1989; 9 Suppl 1: S22.
43. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, et al. Trial of D-α-tocopherol in Huntington's disease. Am J Psychiatry 1995; 152: 1771-5.
44. Roos RA, Pruyt JF, de Vries J, Bots GT. Neuronal distribution in the putamen in Huntington's disease. J Neurol Neurosurg Psychiatry 1985; 48: 422-5.
45. Sax DS, O'Donnell B, Butters N, Menzer L, Montgomery K, Kayne HL. Computed tomographic, neurologic and neuropsychological correlates of Huntington's disease. Int J Neurosci 1983; 18: 21-36.
46. Sharp PF, Smith FW, Gemmell HG, Lyall D, Evans NT, Gvozdanovic D, et al. Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med 1986; 27: 171-7.
47. Spitzer RL, Endicott J. Schedule for affective disorders and schizophrenia - lifetime version (SADS-L). 3rd edn. New York: New York State Psychiatric Institute, Biometrics Research; 1978.
48. Starkstein SE, Brandt J, Folstein S, Strauss M, Berthier ML, Pearlson GD, et al. Neuropsychological and neuroradiological correlates in Huntington's disease. J Neurol Neurosurg Psychiatry 1988; 51: 1259-63.
49. Starkstein SE, Folstein SE, Brandt J, Pearlson GD, McDonnell A, Folstein M. Brain atrophy in Huntington's disease. A CT-scan study. Neuroradiology 1989; 31; 156-9.
50. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme, 1988.
51. Vonsattel JP, Meyers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathologic classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-77.
52. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986; 20: 296-303.
53. Young AB, Penney JB, Starosta-Rubinstein S, Markel D, Berent S, Rothley J, et al. Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch Neurol 1987; 44: 254-7.